{"id":"NCT00848549","sponsor":"Eisai Inc.","briefTitle":"Assessing The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures","officialTitle":"A Randomized, Double-Blind Extension Study To Assess The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-10","primaryCompletion":"2011-06","completion":"2011-11","firstPosted":"2009-02-20","resultsPosted":"2013-01-15","lastUpdate":"2015-12-24"},"enrollment":295,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy"],"interventions":[{"type":"DRUG","name":"Zonisamide","otherNames":["Zonegran"]},{"type":"DRUG","name":"Carbamazepine","otherNames":[]}],"arms":[{"label":"ZNS","type":"ACTIVE_COMPARATOR"},{"label":"CBZ","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to assess the long-term safety and tolerability and to explore the long-term efficacy of zonisamide as monotherapy treatment in subjects with newly diagnosed partial seizures.","primaryOutcome":{"measure":"Percentage of Participants Remaining in the Study at Each Visit","timeFrame":"At 3, 6, 9, 12, 15, 18, 21, 24, and 27 months","effectByArm":[{"arm":"Zonisamide","deltaMin":95.6,"sd":null},{"arm":"Carbamazepine","deltaMin":93.7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":133,"countries":["Australia","Denmark","France","Germany","Greece","Hungary","India","Italy","Montenegro","Poland","Russia","Serbia","Slovakia","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":137},"commonTop":["Headache","Somnolence","Dizziness","Weight Decreased","Decreased appetite"]}}